Drug Profile

OPN 5667

Alternative Names: OPN-5667

Latest Information Update: 09 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Opna Bio
Class Antineoplastics
Mechanism of Action CREB-binding protein degraders; EP300 protein degraders; IKZF1 protein degraders; IKZF3 protein degraders

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Multiple myeloma

Most Recent Events

08 Dec 2025 Preclinical trials in Multiple myeloma in Switzerland (unspecified route) prior to December 2025
08 Dec 2025 Pharmacodynamics data from a preclinical study in Multiple myeloma released by Opna Bio
06 Dec 2025 Pharmacodynamics data from a preclinical study in Multiple myeloma presented at 67^th American Society of Hematology Annual Meeting and Exposition (ASH-HEM-2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com